{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-005707","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.419082+00:00","generated_at":"2026-05-31T09:18:51.254123+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phio Pharma Q2 net loss $1.8M, cash $4.7M; PH-762 trial progresses","bullets":["Cash at June 30, 2024: $4.7M vs $8.5M at Dec 31, 2023; net loss $1.8M vs $2.5M year ago.","Phase 1b trial for PH-762 received positive SMC safety recommendation; dose escalation and next cohort enrollment ongoing.","Nasdaq compliance regained for minimum $1.00 bid price after 9:1 reverse stock split effective July 5, 2024.","Appointed Robert M. Infarinato as VP and CFO effective August 1, 2024.","Entered exploratory collaboration with global skin care company for INTASYL cosmeceutical compounds."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-005707","json":"https://secwatch.observer/filing/0001683168-24-005707.json","markdown":"https://secwatch.observer/filing/0001683168-24-005707.md","text":"https://secwatch.observer/filing/0001683168-24-005707.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824005707/0001683168-24-005707-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824005707/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:18:51.254123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}